Stay updated on Adaptive Dosing of Ipilimumab and Nivolumab Clinical Trial

Sign up to get notified when there's something new on the Adaptive Dosing of Ipilimumab and Nivolumab Clinical Trial page.
Latest website image capture
Clouds background image

Latest updates to the Adaptive Dosing of Ipilimumab and Nivolumab Clinical Trial page

  1. Check
    today
    No Change Detected
  2. Check
    yesterday
    No Change Detected
  3. Check
    2 days ago
    Change Detected
    Summary
    The value of Revision has been updated from v2.8.0 to v2.8.1, indicating a recent revision in the content of the webpage.
    Difference
    0.1%
    Check dated 2024-06-13T21:04:20.000Z thumbnail image
  4. Check
    4 days ago
    No Change Detected
  5. Check
    5 days ago
    No Change Detected
  6. Check
    10 days ago
    Change Detected
    Summary
    The value 7 has recently changed to 8 on the webpage, indicating a potential update in the number of doses being evaluated in a Phase II study on adaptive dosing of Ipilimumab and Nivolumab combination immunotherapy for metastatic melanoma patients.
    Difference
    0.1%
    Check dated 2024-06-06T14:23:58.000Z thumbnail image
  7. Check
    25 days ago
    Change Detected
    Summary
    The value 'Participation Criteria 6' has been updated to 'Participation Criteria Researchers look for people who fit a certain description, called eligibility criteria.' This change provides a more detailed explanation of eligibility criteria, including examples such as a person's general health condition or prior treatments.
    Difference
    38%
    Check dated 2024-05-22T20:33:28.000Z thumbnail image
  8. Check
    43 days ago
    Change Detected
    Summary
    The value (Estimated) has recently changed to . This change represents an update in the estimated primary completion date for the study evaluating adaptive dosing of Ipilimumab and Nivolumab combination immunotherapy for patients with metastatic melanoma.
    Difference
    0.1%
    Check dated 2024-05-04T09:48:14.000Z thumbnail image
  9. Check
    44 days ago
    Change Detected
    Summary
    The value on the webpage related to a study on adaptive dosing of Ipilimumab and Nivolumab combination immunotherapy has changed from an estimated study completion date of April 2024 to a new estimated completion date of May 2024. This change may indicate a shift in the timeline for evaluating the effectiveness of the treatment regimen in patients with metastatic melanoma.
    Difference
    1%
    Check dated 2024-05-03T08:13:47.000Z thumbnail image
  10. Check
    46 days ago
    Change Detected
    Difference
    1%
    Check dated 2024-04-30T22:35:05.000Z thumbnail image

Stay in the know with updates to Adaptive Dosing of Ipilimumab and Nivolumab Clinical Trial

Enter your email address, and we'll notify you when there's something new on the Adaptive Dosing of Ipilimumab and Nivolumab Clinical Trial page.